{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-NHL&page=2", "query": { "condition": "B-NHL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=B-NHL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T22:24:47.373Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00720876", "title": "Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "vorinostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-07-23", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 3, "location_summary": "Beverly Hills, California • Duarte, California • Pasadena, California", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720876" }, { "nct_id": "NCT05360238", "title": "Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular B-cell Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma Recurrent", "Mantle Cell Lymphoma Refractory", "Small Lymphocytic Lymphoma, Relapsed", "Waldenstrom's Macroglobulinemia Recurrent", "Waldenstrom's Macroglobulinemia Refractory", "Chronic Lymphoid Leukemia in Relapse", "B-cell Lymphoma Refractory" ], "interventions": [ { "name": "MB-106", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mustang Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-05-24", "completion_date": "2024-04-12", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 6, "location_summary": "Orange, California • Boston, Massachusetts • New York, New York + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05360238" }, { "nct_id": "NCT05319028", "title": "Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-GCB/ABC Diffuse Large B-Cell Lymphoma", "With and Without MyD88 and/or CD79B Mutations" ], "interventions": [ { "name": "Mivavotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 2, "start_date": "2022-06-23", "completion_date": "2023-02-24", "has_results": false, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 7, "location_summary": "Evanston, Illinois • Detroit, Michigan • Cleveland, Ohio + 4 more", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Toledo", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05319028" }, { "nct_id": "NCT01239394", "title": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "ofatumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2010-12", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-10-18", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01239394" }, { "nct_id": "NCT00933985", "title": "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemias of Ambiguous Lineage", "Acute Undifferentiated Leukemia", "Angioimmunoblastic T-cell Lymphoma", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Small Intestine Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "dexrazoxane hydrochloride", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "obatoclax mesylate", "type": "DRUG" }, { "name": "liposomal vincristine sulfate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 22, "start_date": "2009-06", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00933985" }, { "nct_id": "NCT05432635", "title": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Mantle Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Anti-CD19-CAR CMV-specific T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine", "type": "BIOLOGICAL" }, { "name": "Myeloablative Conditioning", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-08-01", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432635" }, { "nct_id": "NCT00002471", "title": "Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "asparaginase", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1990-02", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002471" }, { "nct_id": "NCT01118013", "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "donor lymphocytes", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "reduced-intensity transplant conditioning procedure", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "69 Years", "sex": "ALL", "summary": "Up to 69 Years" }, "enrollment_count": 6, "start_date": "2010-12", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 10, "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Elkton MD", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01118013" }, { "nct_id": "NCT02594384", "title": "A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic" ], "interventions": [ { "name": "LAM-002A", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OrphAI Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2015-10", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 11, "location_summary": "Huntsville, Alabama • Jacksonville, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02594384" }, { "nct_id": "NCT00949052", "title": "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "DNA analysis", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "evaluation of cancer risk factors", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2009-01", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-06-10T22:24:47.373Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00949052" } ] }